From ā¹51 Cr to ā¹1,272 Cr in a yearāthis Indian biotechās revenue chart is insane. š° Molbio is going public targeting ā¹22,000ā24,000 Cr valuation. IPO expected in November 2025, raising ā¹2,200ā2,400 Cr. š¬ Their Truenat platform, is a battery-powered real-time PCR system. PCR (Polymerase Chain Reaction) enables rapid amplification and detection of specific DNA sequences. šļøšØ It brought rapid TB, COVID-19, and infectious disease testing to 8,300+ clinics worldwide. WHO approved their TB testing. šø Molbioās Massive Revenue Swings: - FY20: ā¹51 Cr - FY21: ā¹1,272 Cr (25x growth from COVID-19 testing) - FY22: ā¹776 Cr - FY23: ā¹332 Cr (post-pandemic dip) - FY24: ā¹850 Cr - FY25 (Projected): ā¹1,200 Cr Their main competitor in India & abroad is American company Cepheid. Cepheid (owned by Danaher) is one of the biggest players in molecular diagnostics. šø Cepheidās Revenue (estimated from Danaherās reports): - FY20: $2 billion ā ā¹16,600 Cr - FY21: $2.88 billion ā ā¹23,904 Cr - FY23: $2.9 billion ā ā¹24,070 Cr - FY24: $2.25 billion ā ā¹18,675 Cr Cepheidās massive sales figures show how big Point-of-Care PCR diagnostics market can be. āWith Molbioās IPO raise, can they scale worldwide and challenge global giant Cepheid? āWould you invest in a biotech IPO over SaaS/Gig Economy companies? š ---------------------------------- https://www.molbiodiagnostics.com https://bigteclabs.com
Download the medial app to read full posts, comements and news.